Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article

Yvonne Bosch¹*, Raed Al Dieri², Hugo ten Cate³, Patty Nelemans⁴, Saartje Bloemen², Coenraad Hemker², Patrick Weerwind¹, Jos Maessen¹ and Baheramsjah Mochtar²

Abstract

Background: In this study the value of thrombin generation parameters measured by the Calibrated Automated Thrombography for prediction of blood loss after cardiac surgery with cardiopulmonary bypass was investigated.

Methods: Thirty male patients undergoing first-time coronary artery bypass grafting were enrolled. Blood samples were taken pre-bypass before heparinisation (T1) and 5 min after protamine administration (T2). Thrombin generation was measured both in platelet-rich plasma and in platelet-poor plasma. Besides thrombin generation measurements, activated clotting time, haematocrit, haemoglobin, platelet number, fibrinogen, antithrombin, D-dimers, prothrombin time and activated partial thromboplastin time were determined. Blood loss was measured and the amount of transfusion products was recorded postoperatively until 20 hours after surgery. Patients were divided into two groups based on the median volume of postoperative blood loss (group 1: patients with median blood loss < 930 ml; group 2: patients with median blood loss ≥ 930 ml).

Results: On T1, patients of group 2 had a significantly lower endogenous thrombin potential and peak thrombin (p<0.001 and p=0.004 respectively) in platelet-rich plasma, a significantly lower endogenous thrombin potential (p=0.004) and peak thrombin (p=0.014) in platelet-poor plasma, and a lower platelet count (p=0.002). On T2 both endogenous thrombin potential and peak thrombin remain significantly lower (p=0.011 and p=0.010) in group 2, measured in platelet-rich plasma but not in platelet-poor plasma. In addition, platelet number remains lower in group 2 after protamine administration (p=0.002).

Conclusions: The key finding is that the Calibrated Automated Thrombography assay, performed preoperatively, provides information predictive for blood loss after cardiac surgery.

Keywords: Bleeding, Blood (anti)coagulation, Blood loss, Thrombin generation, CABG, CPB

Background

Blood loss and thrombotic incidents still belong to the most frequent and feared complications in cardiac surgery with cardiopulmonary bypass (CPB) [1], despite of preoperative evaluation of the haemostatic condition by assessment of medical history and common coagulation tests [2,3]. Disturbed haemostasis can be attributed to abnormal thrombin generation (TG), platelet dysfunction and excessive fibrinolysis. Anticoagulation with high doses of heparin may result in further haemostasis impairment. Currently, tools to adequately predict haemostasis and therefore to control blood loss are lacking. Although it was already shown that the use of thromboelastography (TEG) may help to reduce blood product consumption, studies investigating the relationship between coagulation tests, like TEG, haemostatic variables and bleeding are inconsistent in demonstrating a clear predictive value for the volume of blood loss after CPB [2,4,5]. In part, this inconsistency may be due to the fact that TEG only shows clot formation, not the total amount of thrombin, which plays a central role in haemostasis [6].
In this study, we aimed at investigating the value of thrombin generation parameters as measured by the Calibrated Automated Thrombography (CAT) [6] for the prediction of blood loss after cardiac surgery. This assay displays not only the moment blood starts to clot but also the amount of thrombin that forms in clotting plasma with or without platelets. Conceptually, results of CAT measurements correlate with impaired haemostasis if too low, and with thrombosis risk if too high [7,8]. CAT might improve the timely identification of haemostatic problems underlying a bleeding tendency perioperatively. In this study, we hypothesize that CAT measurement, in comparison with conventional methods, may better predict transfusion management.

**Methods**

**Study population**
The study was approved by the local medical ethics committee (METC aZM/UM), and written informed consent was obtained. In total, 30 male patients undergoing elective first-time coronary artery bypass grafting (CABG) were enrolled. Exclusion criteria were age < 18 years, use of preoperative anticoagulation (excepting aspirin) within the preceding 5 days, known coagulopathy, impaired renal function, liver diseases resulting in elevated liver function tests and redo surgery.

**Anticoagulation and CPB**
An initial dose of 300 IU/kg of body weight of heparin (Heparin Leo, Leo Pharmaceutical Products BV, Weesp, the Netherlands) was injected into a central venous line before initiation of CPB. The kaolin activated clotting time (ACT) was measured and, if the value was ≥400 s, CPB was initiated. If necessary, additional heparin was added. At the end of CPB, heparin was reversed by protamine chloride (Valent Pharmaceuticals, Eschborn, Germany) at a 1:1 ratio of the loading dose.

All components of the CPB system were poly-2-methoxyethylacrylate coated (Terumo).

The priming of the CPB circuit included 1,300 ml of 4% Gelofusine, 200 ml 20% mannitol, 100 ml 20% human albumin, 50 ml 8.4% NaHCO₃ and 6,500 IU heparin Leo. Retrograde autologous priming was used in most of the cases to reduce the priming volume by 200–500 ml, resulting in less haemodilution. Normothermic perfusion was used during CPB. Pericardial, pleural and residual blood of the CPB circuit after termination of CPB was drained and washed with a cell saver device. The transfusion trigger during CPB was set at a haematocrit below 23%.

**Blood samples**
Blood samples were taken at: T1) pre-bypass before heparin administration; and, T2) 5 min after protamine administration. T1 measurements will give information about the predictive value of the parameters prior to haemostatic interventions related to CPB which could suggest differences in baseline haemostatic capacity of the blood between the patients, whereas T2 measurements may give a prediction of blood loss after CPB including the influence of all haemostatic disturbances related to CPB. Blood samples were withdrawn from the arterial line after discarding the first 10 ml.

**Thrombin generation**
Arterial blood samples were collected into trisodium citrate and analyzed with CAT as previously reported [9]. TG was measured both in platelet-rich plasma (PRP) and in platelet-poor plasma (PPP) to see the influence of platelets on TG. PRP was used within 1h after blood withdrawal. PPP was stored at −80°C until further analysis. The CAT assay was measured in a prewarmed plate fluorometer (Ascent reader, Thermolabsystems OY, Helsinki, Finland). To each well, 80 μl of plasma was added in combination with the trigger: for PPP, the trigger was 30 pM of recombinant tissue factor (rTF) and phospholipid vesicles in Heps-buffered saline, for PRP the trigger was 20 μl of 3 pM of rTF without added phospholipids. Data were analyzed using Thrombinscope™ software (Thrombinscope bv, Maastricht, the Netherlands). CAT parameters which are used to determine correlation of TG with postoperative blood loss are: 1) lag time (min): the initiation phase of clotting which equals the clotting time; 2) peak height (nM): the maximal amount of thrombin formed; 3) endogenous thrombin potential (ETP) (nM•min): the area under the curve representing thrombin generation and decay in time; and 4) time to peak (min): the time needed to achieve the peak height.

**ACT and laboratory tests**
Besides CAT measurements, ACT and laboratory parameters haematocrit, haemoglobin, thrombocytes, fibrinogen, antithrombin, D-dimers, prothrombin time (PT) and activated partial thromboplastin time (aPTT) were determined at both time points to assess patient’s haemostatic profile.

**Postoperative blood loss**
Blood loss was measured at fixed time points postoperatively determined by chest tube drainage after closing the chest until 20 hours after surgery. The amount of transfusion products (packed red cells, thrombocytes
or fresh frozen plasma) was recorded until 20 hours after surgery.

**Statistical analysis**

Data were defined as continuous or categorical variables. Categorical variables are expressed as percentages and continuous variables as mean ± standard deviation (SD). Patients were divided into two groups with high versus low blood loss, where the median value of blood loss volume at 20 hours postoperatively was used as cut-off value. Both groups were compared with respect to patient characteristics, medication used pre- and intraoperatively, infusion solutions, mean time on bypass, amount of transfusion products, mean values of CAT parameters and other laboratory parameters. The Chi-square test was used for comparison of proportions and the Student’s t-test for independent samples for comparison of mean values. The ability of CAT and laboratory parameters to discriminate between the two groups was also evaluated by the construction of a receiver operating characteristic (ROC) curve. The corresponding area under the curve (AUC) with 95% confidence interval was used to quantify the predictive value of the parameters. Multivariate linear regression analysis was performed to evaluate the independent effects of parameters. Statistical analysis was performed with SPSS for Windows 16.0 (SPSS, Inc., Chicago, IL, USA). P-values ≤ 0.05 were considered to indicate statistical significance.

**Results**

Thirty male patients were enrolled into the study. One patient was excluded because an exceptionally long term adhesiolysis was necessary to achieve access to the heart resulting in excess blood loss. The distribution of age, preoperative use of aspirin, and intraoperative data relating to the 29 patients are shown in Table 1. In addition to presenting data of the total group, we divided patients in two groups using as cut-off value the median volume of postoperative blood loss until 20 hours (group 1: patients with median blood loss <930 ml; group 2: patients with median blood loss ≥930 ml). The actual blood loss in group 1 was 620 ml, and 1205 ml in group 2. The sample size was based on feasibility considerations. Based on this sample size and the observed standard deviation in group 1 (sd=−/+ 160 ml) the power to detect a clinically relevant increase in mean blood loss by at least 50% (from 620 ml to 930 ml) was higher than 90%.

Differences in both medication and infusion (Table 1) could result in changes in the haemostatic capacity of the blood leading to differences in thrombin generation.

### Table 1 Distribution of patient characteristics and perioperative variables according to postoperative blood loss

|                      | All patients | Group 1 | Group 2 | P-value |
|----------------------|--------------|---------|---------|---------|
|                      | N=29         | N=14    | N=15    |         |
| **Age (years)**      | 65 ± 10      | 67 ± 9  | 64 ± 11 | 0.423   |
| Aspirin exp. preop. n (%) | 27 (93,1%)  | 14 (100%) | 13 (86,7%) | 0.157 |
| **Intraoperatively** |              |         |         |         |
| Tranexam. acid n (%) | 14 (48,3%)   | 9 (64,3%)| 5 (33,3%)| 0.096   |
| Heparin-total (IU/kg)  | 336 ± 54     | 361 ± 66| 314 ± 26| 0.023   |
| Protamine-total (mg/kg)| 3.35 ± 0.52  | 3.55 ± 0.61| 3.17 ± 0.37| 0.048   |
| Crystalloids (ml/kg)  | 16.9 ± 6.5   | 19.8 ± 6.4| 14.2 ± 5.6| 0.018   |
| Colloids (ml/kg)      | 18.6 ± 5.2   | 17.2 ± 4.8| 19.9 ± 5.4| 0.167   |
| PRC (units)*          | 0.0 (0.0-1.0)| 0.0 (0.0-1.0)| 0.0 (0.0-1.0)| 0.591   |
| FFP (units)           | 0 ± 0        | 0 ± 0   | 0 ± 0   | 1       |
| PLT (units)*          | 0.0 (0.0-1.0)| 0.0 (0.0-1.0)| 0.0 (0.0-1.0)| 0.301   |
| PRC cell saver (ml/kg)| 5.7 ± 2.0    | 5.0 ± 1.3| 6.4 ± 2.3| 0.048   |
| Time on bypass (min)  | 76 ± 20      | 70 ± 18 | 81± 22  | 0.160   |
| Time X-clamp (min)    | 48 ± 16      | 45 ± 14 | 52 ± 18 | 0.259   |
| **Postoperatively**   |              |         |         |         |
| Blood loss 20 h (ml)  | 922 ± 384    | 620 ± 160| 1205 ± 307| <0.001  |
| PRC (units)*          | 1.00 (0.0-5.0)| 0.0 (0.0-2.0)| 2.0 (0.0-2.0)| 0.002   |
| FFP (units)*          | 0.0 (0.0-2.0)| 0.0 (0.0-0.0)| 0.0 (0.0-2.0)| 0.164   |
| PLT (units)*          | 0.0 (0.0-1.0)| 0.0 (0.0-0.0)| 0.0 (0.0-1.0)| 0.020   |
| Rethoracotomy n (%)   | 1 (3,4%)     | 0 (0%) | 1 (6,7%)| 0.326   |

Data shown are mean ± SD. Comparison between the groups was done with student t-test; * median and range are presented instead of mean and SD; colloids = infusion volume and priming volume; FFP fresh frozen plasma, PLT platelets, PRC packed red cells.
and, as a consequence, in blood loss. There was no significant difference between aspirin exposure preoperatively between the two groups. Patients in group 2 were infused less crystalloids, and more autologous packed red cells derived from intraoperative cell salvage. Moreover, this group was administered less heparin (total amount of both pre and during CPB) and as a consequence less protamine. Time of bypass and aorta cross clamping were increased in group 2, but differences were not statistically significant.

Thrombin generation parameters measured in platelet-rich and platelet-poor plasma

The mean values (± SD) of TG parameters on T1 and T2 in both PRP and PPP in group 1 versus group 2 are presented in Table 2. Patients of group 2 had a significantly lower ETP and peak thrombin both on T1 and T2. Between group differences in mean values for lag time and time to peak were smaller and not statistically significant. The distributions of ETP and peak values measured in PRP and PPP within groups are shown in Figures 1 and 2.

The AUCs as measures for ability to discriminate between the groups were highest for ETP and peak in PRP at T1 with AUC (95% CI) of 0.881 (0.741-1.021) and 0.855 (0.697-1.013) respectively.

Laboratory tests

The mean values of haemoglobin, haematocrit, platelet number, fibrinogen, D-dimers, antithrombin, PT, aPTT, and ACT at T1 and T2 are shown in Table 3. A significant difference between the groups was only found for platelet number (p=0.002) with lower platelet count in group 2. Differences were also seen for fibrinogen and D-dimers with lower mean values in the group with blood loss ≥930 ml, but only the difference in fibrinogen at T2 achieved statistical significance (p=0.045). Furthermore, it can also be observed that patients with high blood loss had significantly lower haematocrit (%) at T2.

The highest AUC values were observed for platelet number with an AUC (95% CI) of 0.834 (0.690-0.979) at T1 and an AUC (95% CI) of 0.857 (0.705-1.009) at T2. It can also be observed that the AUC of haemoglobin and haematocrit is higher at T2 than at T1 with AUC (95% CI) of 0.714 (0.517-0.912); and 0.732 (0.540-0.924), respectively. AUCs for these parameters at T1 are low. The AUCs associated with fibrinogen and D-dimers are not impressive at both time points with AUCs ranging from 0.547 to 0.703, and the AUC of the variables, aPTT, PT and ACT are below 0.500.

Table 2 TG parameters on T1 and T2, and their association with postoperative blood loss

| PRP | Group 1 (N=14) | Group 2 (N=15) | p  | T1 AUC       | T2 AUC       |
|-----|----------------|----------------|----|--------------|--------------|
| Lag time (min) | 8.7 ± 3.0 | 8.7 ± 3.2 | 7.9 ± 1.4 | 9.4 ± 3.8 | 0.186 | 0.90 ± 3.1 | 8.5 ± 3.4 | 0.700 | 0.452 (0.232-0.672) | 0.543 (0.322-0.764) |
| ETP (nM* min) | 1881 ± 359 | 1524 ± 264 | 2104 ± 207 | 1672 ± 348 | 0.000 | 1649 ± 197 | 1407 ± 270 | 0.011 | 0.881 (0.741-1.021) | 0.800 (0.630-0.970) |
| Peak (nM) | 133 ± 42 | 73 ± 19 | 155 ± 30 | 112 ± 42 | 0.004 | 82 ± 18 | 64 ± 17 | 0.010 | 0.855 (0.697-1.013) | 0.776 (0.605-0.947) |
| Time to peak (min) | 19.3 ± 4.8 | 20.3 ± 5.6 | 18.4 ± 3.5 | 20.2 ± 5.7 | 0.315 | 20.1 ± 5.4 | 20.5 ± 6.0 | 0.870 | 0.381 (0.170-0.592) | 0.493 (0.273-0.713) |

| PPP | Group 1 (N=14) | Group 2 (N=15) | p  | T1 AUC       | T2 AUC       |
|-----|----------------|----------------|----|--------------|--------------|
| Lag time (min) | 2.5 ± 0.5 | 4.2 ± 0.9 | 2.4 ± 0.4 | 2.6 ± 0.6 | 0.368 | 4.2 ± 1.0 | 4.1 ± 0.9 | 0.926 | 0.450 (0.236-0.664) | 0.502 (0.287-0.718) |
| ETP (nM*min) | 1587 ± 355 | 1508 ± 297 | 1774 ± 279 | 1412 ± 336 | 0.004 | 1610 ± 246 | 1411 ± 315 | 0.070 | 0.805 (0.639-0.971) | 0.690 (0.493-0.888) |
| Peak (nM) | 321 ± 63 | 241 ± 36 | 350 ± 48 | 295 ± 64 | 0.014 | 254 ± 31 | 230 ± 36 | 0.070 | 0.771 (0.597-0.946) | 0.700 (0.512-0.745) |
| Time to peak (min) | 4.7 ± 0.7 | 6.7 ± 1.1 | 4.6 ± 0.4 | 4.8 ± 0.9 | 0.332 | 6.8 ± 1.3 | 6.6 ± 1.0 | 0.588 | 0.502 (0.282-0.723) | 0.529 (0.312-0.745) |

Data shown are mean ± SD. Comparison between the groups was done with student t-test. T1 before heparinisation, T2 after protamine administration, AUC area under the curve, ETP endogenous thrombin potential, PPP platelet poor plasma, PRP platelet rich plasma, ROC receiver operating curve.
**Figure 1** ETP on T1 in PRP and PPP in both groups. Boxplot showing median, interquartile range and range of ETP measured before heparinisation in patients of group 1 and 2 on x-axis. P-value of comparison of ETP in PRP between the groups is <0.001, p-value of comparison of ETP in PPP between the groups is 0.004; ETP=endogenous thrombin potential; PPP=platelet poor plasma; PRP=platelet rich plasma.

**Figure 2** Peak thrombin on T1 in PRP and PPP in both groups. Boxplot showing median, interquartile range and range of peak thrombin measured before heparinisation in patients of group 1 and 2 on x-axis. P-value of comparison of peak thrombin in PRP between the groups is 0.004, p-value of comparison of peak thrombin in PPP between the groups is 0.014; PPP=platelet poor plasma; PRP=platelet rich plasma.
Discussion

The present data suggest that the CAT variables ETP and peak thrombin correlate well with the clinically observed bleeding tendency postoperatively in cardiac surgical patients. Patients of group 2 had a significantly lower ETP and peak thrombin, both pre (PRP and PPP) and post CPB (only PRP), than patients in group 1. Concerning the other laboratory parameters, platelet number was the only individual variable measured pre-CPB predicting blood loss postoperatively. Post CPB, besides low fibrinogen a low platelet number was also predictive for blood loss.

Recently Coakley and co-workers demonstrated that TG both pre- and postoperatively could potentially be used to identify patients at an increased risk of bleeding post-CPB [2]. However, they only measured TG in PPP, excluding the influence of platelets, which play a very important role in maintaining normal haemostatic function. It is more representative of the in vivo situation to include the procoagulant functions of platelets [10].

Conventional clot-based methods, have the disadvantage of measuring only the moment of clot formation and ensuing changes in the properties of the clot. Clot formation is only one of the many functions of thrombin and not necessarily the most important one. Thrombin also activates platelets, and furthermore, besides procoagulant effects it has also anticoagulant effects following its binding to thrombomodulin. Ex vivo TG tests, like CAT, measure the haemostatic function of the blood, determined by simultaneous prothrombin activation and thrombin inactivation [9]: it measures the remaining capacity of blood to generate a thrombin burst indicating an increased risk of thrombosis or bleeding [11]. In contrast, in vivo TG, revealed by products like prothrombin fragment F1+2, thrombin antithrombin complex, and d-dimers, provides indications of TG that has already occurred [12] at the moment of blood collection.

Since the lag time represents the same aspect as in standard coagulation assays, this is comparable with aPTT and PT. Our results showed that both aPTT and PT as well as lag time were not different between the groups. These tests terminate with endpoints that occur with less than 5% of the reaction complete [13]. Apparently, the

| Table 3 Laboratory parameters on T1 and T2, and their association with postoperative blood loss |
|-----------------------------------------------|
| **T1** (N=29) | **T2** (N=29) | **T1** (N=14) | **T2** (N=15) | **p** | **T1** (N=14) | **T2** (N=15) | **p** | **T1 AUC (95% CI)** | **T2 AUC (95% CI)** |
|-----------------------------------------------|
| Hemoglobin (mmol/l) | 7.8 ± 0.6 | 5.4 ± 0.5 | 7.7 ± 0.5 | 7.8 ± 0.8 | 0.345 | 5.6 ± 0.5 | 5.3 ± 0.4 | 0.098 | 0.377 | (0.165-0.590) | 0.714 | (0.517-0.912) |
| Hematocrit (%) | 37.2 ± 3.3 | 25.9 ± 2.3 | 36.8 ± 2.6 | 37.7 ± 3.8 | 0.475 | 26.8 ± 2.2 | 25.1 ± 2.2 | 0.044 | 0.401 | (0.186-0.617) | 0.732 | (0.540-0.924) |
| Platelet number (*10^9/l) | 215 ± 61 | 128 ± 42 | 249 ± 57 | 184 ± 48 | 0.002 | 152 ± 40 | 105 ± 31 | 0.002 | 0.834 | (0.690-0.979) | 0.857 | (0.705-1.009) |
| Fibrinogen (g/l) | 2.9 ± 0.7 | 1.7 ± 0.4 | 3.1 ± 0.8 | 2.7 ± 0.5 | 0.198 | 1.9 ± 0.5 | 1.5 ± 0.3 | 0.045 | 0.627 | (0.419-0.855) | 0.703 | (0.512-0.894) |
| D-dimers (ng/ml) | 700 ± 782 | 1109 ± 1146 | 949 ± 1063 | 467 ± 235 | 0.119 | 1083 ± 1069 | 1132 ± 1251 | 0.909 | 0.654 | (0.442-0.866) | 0.547 | (0.333-0.761) |
| Antithrombin (%) | 80.9 ± 11.5 | 49.6 ± 6.6 | 80.1 ± 7.8 | 81.6 ± 14.4 | 0.727 | 50.1 ± 7.1 | 49.0 ± 6.3 | 0.651 | 0.440 | (0.229-0.651) | 0.574 | (0.364-0.783) |
| PT (sec) | 11.5 ± 0.5 | 15.4 ± 1.5 | 11.4 ± 0.6 | 11.5 ± 0.4 | 0.417 | 15.2 ± 1.3 | 15.7 ± 1.6 | 0.341 | 0.425 | (0.205-0.646) | 0.373 | (0.168-0.577) |
| aPTT (sec) | 28.9 ± 3.2 | 34.6 ± 5.5 | 28.9 ± 3.9 | 28.8 ± 2.7 | 0.922 | 34.1 ± 5.6 | 35.1 ± 5.5 | 0.634 | 0.498 | (0.276-0.719) | 0.406 | (0.197-0.615) |
| ACT (sec) | 132 ± 15 | 140 ± 17 | 134 ± 18 | 131 ± 12 | 0.625 | 140 ± 15 | 141 ± 19 | 0.875 | 0.498 | (0.281-0.714) | 0.487 | (0.275-0.698) |

Data shown are mean ± SD. Comparison between the groups was done with student t-test. T1 before heparinisation, T2 after protamine administration, ACT activated clotting time, aPTT activated partial thromboplastin time, PT prothrombin time.

Tables 4 and 5, and results for the other measurements are similar.

| Table 4 Independent effects of platelets and ETP in PRP on blood loss by linear regression analysis |
|-----------------------------------------------|
| **Univariate** | **Multivariate** |
|-----------------------------------------------|
| **B Unstandardized** | **B Standardized** | **p-value** | **B Unstandardized** | **B Standardized** | **p-value** |
| ETP (nM* min) | −0.429 | −0.401 | 0.031 | −0.322 | −0.301 | 0.144 |
| Platelet number (*10^9/l) | −2.223 | −0.354 | 0.060 | −1.325 | −0.211 | 0.301 |

B regression coefficient, ETP endogenous thrombin potential.
Concerning coagulation factors we only measured fibrinogen. This factor demonstrated to be higher both pre- and postoperatively in group 1, but the difference was only statistically significant postoperatively. In the study of Coakley [2] coagulation factor levels were determined postoperatively in groups that either bled more than 1L or less than 1L. Fibrinogen level was the same in both groups, in contrast with our results. Karlsson et al. [15] investigated the relationship between preoperative fibrinogen plasma concentration and postoperative bleeding after CABG surgery. Their main finding was that higher preoperative fibrinogen was correlated with less blood loss postoperatively. Despite of the important contribution of fibrinogen in the coagulation process, our study results indicate that fibrinogen level is less strongly associated with blood loss than TG parameters. This is remarkable because, although fibrinogen is depleted before 5% of all thrombin is formed [11], thrombin bound to fibrin has a positive feedback activation on the coagulation system and is protected from inactivation to the action of antithrombin and heparin [16].

Table 5 Independent effects of platelets and peak-thrombin in PRP on blood loss by linear regression analysis

|                | Univariate |          | Multivariate |          |
|----------------|------------|----------|--------------|----------|
|                | B Unstandardized | B Standardized | p-value | B Unstandardized | B Standardized | p-value |
| Peak (nM)      | −0.2897   | −0.319   | 0.092        | −2.026   | −2.223   | 0.253       |
| Platelet number (*10^9/l) | −2.223   | −0.354   | 0.060        | −1.737   | −0.276   | 0.159       |

B: regression coefficient.

Remarkable is the significantly higher dose of intraoperative heparin in group 1. Most probably a higher dose of heparin is administered in this group as a result of a relatively high platelet count in this group [17]: the concentration of heparin required to inhibit or delay coagulation is directly related to the number of platelets [18], probably due to the capacity of platelet released platelet factor 4 neutralizing heparin [19,20].

Patients who bled more, were administered proportionally less crystalloids and more colloids. Colloids are known to affect clot formation by reducing fibrinogen concentration and disturbing fibrin polymerization [21] demonstrated by thromboelastography assay. Schols et al. found that colloids reduce the formation of fibrin clots but affect TG only at clinically irrelevant high concentrations [22]. The volume of colloids administered was not significantly different between the groups.

Group 2 is characterized by a higher supplementation of transfusion products. In addition, these patients had a higher intraoperative blood loss, as shown by a higher amount of PRC volume processed by cell salvage. Despotis et al. also demonstrated that greater volumes of intraoperative salvaged red cells were associated with excessive blood loss and use of blood products [23], explained by the fact that greater volumes of salvaged red cells primarily reflects excessive blood loss intraoperatively but proceeding postoperatively. Another explanation may be that extensive intraoperative cell salvage caused a significant loss of platelets and plasma resulting in postoperative bleeding.

The strength of this study is that CAT, performed preoperatively, is able to predict blood loss after cardiac surgery. Preoperative measurements (T1) exclude the haemostatic effects caused by exposure of the blood to different non-physiological conditions. The predictive value of CAT performed postoperatively (T2) for blood loss will be influenced by a lot of interventions like heparinisation, fluid administration (crystalloid and/or colloid), administration of tranexamic acid and protamine, time on bypass, and transfusion product requirements intraoperatively. All these factors interfere at different levels in the haemostatic balance of the patients what makes the prediction of blood loss by CAT parameters weaker at T2 (AUCs are lower at T2).

The main limitation of the study is the low number of participants (n=30). P-values in the multivariate linear
regression models were higher or even no longer statistically significant, possibly due to small sample size. The results should be considered as preliminary. Changes in haemostatic factors would have been more reliable in a larger number of patients. Another limitation of the study is that it could not account for variations in routine practice in the ICU that may have influenced blood loss, such as amount and timing of platelet and plasma transfusions. Especially in the bleeding group the amount of blood loss should be influenced by platelet and plasma transfusion. Therefore, additional larger clinical, and preferable intervention, studies are required to establish profound clinical relevance.

Conclusions

The key finding is that the Calibrated Automated Thrombography assay, performed preoperatively, provides information predictive for non-surgical blood loss after cardiac surgery, and might be considered as a standard screening test to assess the haemostatic condition preoperatively. Improved haemostatic management of patients undergoing cardiac surgery, especially high risk patients, requires more knowledge on the changes in TG, and on proactive interventions like administration of haemostatic-augmenting pharmacologic agents or blood components. Identifying patients at increased risk of bleeding will become easier because techniques for measuring TG in whole blood as a bedside method are in development, so that the outcome of a study with the CAT can, in the future, be more easily applied in clinical settings.

Abbreviations

CAT: Calibrated automated thrombography; TG: Thrombin generation; PRP: Platelet rich plasma; PPP: Platelet poor plasma; ETP: Endogenous thrombin potential; CPB: Cardiopulmonary bypass; TEG: Thromboelastography; CAB: Coronary artery bypass grafting; ACT: Activated clotting time; rTF: Recombinant tissue factor; PT: Prothrombin time; aPT: Activated partial thromboplastin time; ROC: Receiver operating curve; AUC: Area under the curve; PRC: Packed red cells; FFP: Fresh frozen plasma; PLT: Platelets.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

YB, RA, HC, CH, and BM designed the study. YB collected the clinical data. RA Maastricht, Maastricht University Medical Center, PO Box 616, 6200, MD, Maastricht, the Netherlands. *Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, P. Debyeelaan 25, PO Box 5800, 6200, AZ, Maastricht, the Netherlands. 2Department of Internal Medicine, Maastricht University Medical Center, P. Debyeelaan 25, PO Box 5800, 6202, AZ, Maastricht, the Netherlands. 3Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, PO Box 616, 6200, MD, Maastricht, the Netherlands. 4Department of Epidemiology, Maastricht University Medical Center, PO Box 616, 6200, MD, Maastricht, the Netherlands. *Department of Epidemiology, Maastricht University Medical Center, PO Box 616, 6200, MD, Maastricht, the Netherlands. 5Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, PO Box 616, 6200, MD, Maastricht, the Netherlands. 6Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, PO Box 616, 6200, MD, Maastricht, the Netherlands. 7Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, PO Box 616, 6200, MD, Maastricht, the Netherlands. 8Department of Internal Medicine, Maastricht University Medical Center, PO Box 616, 6200, MD, Maastricht, the Netherlands. 9Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, PO Box 616, 6200, MD, Maastricht, the Netherlands. 10Department of Internal Medicine, Maastricht University Medical Center, PO Box 616, 6200, MD, Maastricht, the Netherlands.

Received: 4 October 2012 Accepted: 6 June 2013

References

1. Groenenberg I, Weerwind PW, Everts PAM, Maessen JG: Dutch perfusion incident survey. Perfusion 2010, 25:329–336.
2. Cockley M, Hall JE, Evans C, Duff E, Billing V, Yang L, McPherson D, Stephens E, Macnery N, Wilkes AR, Collins PW: Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding. J Thromb Haemost 2011, 9:282–292.
3. Innerhofer P, Kienast J: Principles of perioperative coagulopathy. Best Pract Res Clin Anaesthesiol 2010, 24:1–14.
4. Luddington RJ: Thrombelastography/thromboelastometry. Clin Lab Haematol 2005, 27:81–90.
5. Reinhofer M, Brauer M, Franke U, Barz D, Marx G, Losche W: The value of rotation thromboelastometry to monitor disturbed perioperative haemostasis and bleeding risk in patients with cardiopulmonary bypass. Blood Coagul Fibrolysis 2008, 19:212–219.
6. Hemker HC, Giesen P, Al Dieri R, Regnault V, De Smedt E, Wagenvoord R, Lecompte T, Beguin S: The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002, 32:249–253.
7. Al Dieri R, Peyvandi F, Santagostino E, Gianfily M, Mannucci PM, Schved JF, Beguin S, Hemker HC: The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002, 88:576–582.
8. Orbe J, Zudaire M, Serrano R, Coma-Canella I: Martinez de Sizarrondo S, Rodriguez JA, Paramo JA: Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test, Thromb Haemost 2008, 99:382–387.
9. Hemker HC, Giesen P, Al Dieri R, Regnault V, De Smedt E, Wagenvoord R, Lecompte T, Beguin S: Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003, 33:4–15.
10. Hemker HC, Beguin S: Phenotyping the clotting system. Thromb Haemost 2000, 84:747–751.
11. Hemker HC, Al Dieri R, Beguin S: Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 2004, 11:170–175.
12. Wong RK, Sleep JR, Visner AJ, Raasch DJ, Lanza LA, De Valeria PA, Torloni AS, Arabia FA: Thromboelastography reveals thrombin generation potential continues to deteriorate following cardiopulmonary bypass surgery despite adequate hemostasis. J Extra Corpor Technol 2011, 43:19–25.
13. Mann KG, Brummel K, Butenas S: What is all that thrombin for? J Thromb Haemost 2003, 1:1504–1514.
14. Heemskerk JWR, Bevers EM, Lindhout T: Platelet activation and blood coagulation. Thromb Haemost 2002, 88:186–193.
15. Karlsson M, Ternstrom L, Hyllner M, Baghai F, Nilsson S, Jeppsson A: Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study, Transfusion 2008, 48:2152–2158.
16. Kumar R, Beguin S, Hemker HC: The influence of fibrinogen and fibrin on thrombin generation–evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994, 72:713–721.
17. Bosch YPJ, Weerwind PW, Nelemans PJ, Maessen JG, Mochtar B: An evaluation of factors affecting activated coagulation time. J Cardiothorac Vasc Anesth 2012, 26:563–568.
18. Conley CL, Hartmann RC, Lailey JS: The relationship of heparin to platelet concentration, Proc Soc Exp Biol Med 1948, 69:284–287.
19. Home MK 3rd, Chao ES: Heparin binding to resting and activated platelets. Blood 1989, 74:238–243.
20. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U: Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1988, 248:725–732.
21. Innerhofer P, Fries D, Margreiter J, Klingler A, Kubbacher G, Wachtler B, Oswald E, Salier E, Frischhut B, Schobesberger W: The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesth Analg 2002, 95:858–865.
22. Schols SE, Feijge MA, Lance MD, Hamulyak K, Ten Cate H, Heemskerk JW, Van Pampus EC: Effects of plasma dilution on tissue-factor-induced thrombin generation and thromboelastography: partly compensating role of platelets. Transfusion 2008, 48:2384–2394.

23. Despotis GJ, Filos KS, Zibys TN, Hogue CW Jr, Spitznagel E, Lappas DG: Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996, 82:13–21.

doi:10.1186/1749-8090-8-154

Cite this article as: Bosch et al: Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article. Journal of Cardiothoracic Surgery 2013 8:154.